Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.52 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.51 |
| ▸ | DPP4 | P27487 | 2/20 | 0.48 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | TGM2 | P21980 | 2/20 | 0.47 |
| ▸ | ACE | P12821 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9976419 | 0.89 | FOLH1 (0.56) | DPP8DPP7FOLH1MMP2MMP9 | |
| SCHEMBL18337922 | 0.89 | FOLH1 (0.56) | DPP8DPP7FOLH1MMP2MMP9 | |
| SCHEMBL8613001 | 0.86 | FOLH1 (0.52) | DPP8DPP7FOLH1TGM2HTT | |
| SCHEMBL12727090 | 0.84 | FOLH1 (0.54) | DPP8DPP7FOLH1DPP4DPP9 | |
| SCHEMBL16557260 | 0.83 | FOLH1 (0.67) | DPP8DPP7FOLH1MMP2MMP9 | |
| SCHEMBL356734 | 0.83 | KLK7 (0.63) | FOLH1 | |
| SCHEMBL2803734 | 0.83 | KLK7 (0.63) | FOLH1 | |
| SCHEMBL8209334 | 0.82 | HTT (0.53) | DPP8DPP7FOLH1DPP4DPP9 | |
| SCHEMBL11294170 | 0.81 | HTT (0.52) | DPP8DPP7FOLH1DPP4DPP9 | |
| SCHEMBL11048769 | 0.81 | HTT (0.52) | DPP8DPP7FOLH1DPP4DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160213742-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2016-07-28 | — | — | US | disclosed |
| US-20160213742-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2016-07-28 | — | — | US | disclosed |
| WO-2015035102-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160213742-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | FPR1, FPR3, FPR2 | DPP8 1179/4885DPP7 1039/4885FOLH1 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.